drugset / Trial / NCT01144663

Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines

NCT01144663

Phase 3 Completed 2095 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate immunogenicity and safety of meningococcal conjugate vaccine GSK134612 compared to the licensed vaccines MenC-CRM197 and MenC-TT in infants of 2 months of age. Pneumococcal conjugate vaccine and DTPa-HBV-IPV/Hib vaccines will be co-administered.

Timeline

Start
2010-07-01
Primary completion
2012-06-22
Completion
2013-09-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Menjugate Vaccine Intramuscular
Subject Menveo Vaccine Intramuscular
Comparator NeisVac-CTM Unknown Intramuscular
Background Infanrix hexa Vaccine Intramuscular
Background Synflorix Vaccine Intramuscular